[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657214":3},{"organization":4,"outcomesModule":7,"designInfo":89,"detailedDescription":95,"studyPopulation":88,"armGroups":96,"interventions":109,"overallOfficials":88,"centralContacts":124,"locations":130,"responsibleParty":146,"collaborators":88,"id":148,"slug":149,"hasResults":150,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":88,"eligibilityCriteria":154,"healthyVolunteers":150,"sex":155,"minAge":156,"maxAge":88,"enrollmentInfo":157,"targetDuration":88,"studyType":160,"phases":161,"briefSummary":163,"conditions":164,"keywords":88,"overallStatus":166,"whyStopped":88,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":88},[9],{"measure":10,"description":11,"timeFrame":12},"Efficacy rate of frailty intervention at 1 month after the last treatment","Calculation formula: \\[(Baseline score - Follow-up score at 1 month after the last treatment) \u002F Baseline score\\] × 100%. This rate represents the degree of improvement in patients' frailty status following intervention.","1 month after the last treatment",[14,18,22,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,74,78,81,84],{"measure":15,"description":16,"timeFrame":17},"Efficacy rate of frailty intervention assessed by FRAIL Scale","The efficacy rate of frailty intervention calculated based on the FRAIL Scale (Fatigue, Resistance, Ambulation, Illnesses, Loss of weight). The scale ranges from 0 (no frailty) to 5 (severe frailty); higher scores indicate worse frailty status. Efficacy rate = (Baseline score - Score at follow-up) \u002F Baseline score × 100%.","Baseline, 4 week, 8 week, 12 week, 16 week, 20 week, 24 week, 28 week, and 32 week after enrollment",{"measure":19,"description":20,"timeFrame":21},"Strand specificity of frailty-related cfDNA and therapeutic response to plasma exchange","Assess strand specificity of frailty-related circulating cell-free DNA and evaluate its predictive value for plasma exchange treatment response.","Baseline, 1 month and 6 months after the last treatment",{"measure":23,"description":24,"timeFrame":25},"Clonal hematopoiesis gene mutation dynamics and correlation with frailty","Observe clonal hematopoiesis-associated gene mutation and clonal evolution at baseline, 1 month and 6 months post last treatment; explore the correlation between clonal hematopoiesis features and frailty status.","Baseline, 4 week,24 week, 28 week, and 32 week after enrollment",{"measure":27,"description":28,"timeFrame":21},"BCR clonotype characteristics","Analysis of BCR clonotype derived from identical BCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.",{"measure":30,"description":31,"timeFrame":21},"BCR V\u002FJ gene usage bias","Analysis of BCR V\u002FJ gene usage bias derived from identical BCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.",{"measure":33,"description":34,"timeFrame":21},"BCR diversity index","Analysis of BCR diversity index derived from identical BCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.",{"measure":36,"description":37,"timeFrame":21},"Frequency of senescence-associated antigen-specific B cell clones","Analysis of senescence-associated antigen-specific B cell clones derived from identical BCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.",{"measure":39,"description":40,"timeFrame":21},"TCR clonotype characteristics","Analysis of TCR clonotype derived from a single unified TCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.",{"measure":42,"description":43,"timeFrame":21},"TCR diversity index","Analysis of TCR diversity index derived from a single unified TCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.",{"measure":45,"description":46,"timeFrame":21},"TCR V\u002FJ gene usage bias","Analysis of TCR V\u002FJ gene usage bias derived from a single unified TCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.",{"measure":48,"description":49,"timeFrame":21},"Frequency of senescence-associated antigen-specific T cell clones","Analysis of senescence-associated antigen-specific T cell clones derived from a single unified TCR high-throughput sequencing assay. Assessments are performed at baseline, 1 month and 6 months after the last treatment.",{"measure":51,"description":52,"timeFrame":17},"Between-group differences in frailty scale score: ALB group vs ALB+IVIg group","Compare the changes of frailty scale score between albumin monotherapy group and albumin combined with IVIg group.",{"measure":54,"description":55,"timeFrame":12},"Baseline changes of serum ALB modification at 1 month after last treatment","Evaluate the alterations of serum albumin subtypes including oxidation, glycation, nitration, sulfenylation, cysteinylation, cysteinylation combined with glycation versus baseline.",{"measure":57,"description":58,"timeFrame":12},"Changes from baseline in senescence-related indicators at 1 month after last treatment","Detect plasma proteome and glycoproteome related to senescence, including SASP, serum inflammatory factors and epigenetic senescence clock, and analyze their changes compared with baseline.",{"measure":60,"description":61,"timeFrame":17},"Changes from baseline in Tilburg Frailty Indicator (TFI) scores","To evaluate the changes of Tilburg Frailty Indicator (TFI) score compared with baseline at each follow-up time point.",{"measure":63,"description":64,"timeFrame":17},"Changes from baseline in Fried Frailty Phenotype Scale scores","To evaluate the change of Fried Frailty Phenotype Scale score compared with baseline.\n\nThis is one single outcome indicator (scale score) assessed repeatedly at multiple planned follow-up time points, not multiple distinct outcome measures.This represents one continuous outcome (Frailty Phenotype score) assessed longitudinally at multiple prespecified time points.",{"measure":66,"description":67,"timeFrame":17},"Changes from baseline in physical and mental health questionnaire scores","Assess changes from baseline in EQ-5D, PROMIS-29, Generalized Anxiety Disorder (GAD) scale, Patient Health Questionnaire (PHQ), Pittsburgh Sleep Quality Index (PSQI).",{"measure":69,"description":70,"timeFrame":17},"Short Physical Performance Battery (SPPB) score","To evaluate patients' physical function using the Short Physical Performance Battery (SPPB). This single continuous scale outcome will be repeatedly assessed at multiple scheduled follow-up time points.",{"measure":72,"description":73,"timeFrame":21},"Changes in gene mutation frequency and its correlation with immune cell subsets","Analyze the shift of gene mutation frequency before and after treatment, and explore the correlation between mutation frequency and immune cell profiles.",{"measure":75,"description":76,"timeFrame":77},"Changes from baseline in CRP","Detect serum CRP, and calculate their changes compared with baseline at predefined visits.","Baseline, 4 week, 24 week, 28 week, and 32 week after enrollment",{"measure":79,"description":80,"timeFrame":77},"Changes from baseline in ESR levels","Detect serum erythrocyte sedimentation rate (ESR) , and calculate their changes compared with baseline at predefined visits.",{"measure":82,"description":83,"timeFrame":77},"Changes from baseline in ferritin levels","To assess changes in serum ferritin concentration relative to baseline.",{"measure":85,"description":86,"timeFrame":87},"Incidence of adverse events during treatment","The incidence rate of all adverse events occurring during the treatment period will be calculated. Focused adverse events include catheter-related infections, hypersensitivity reactions, thrombosis, and other related adverse events.","From initiation of the first treatment through 6-month after completion of all study treatments, assessed up to 12 months",null,{"allocation":90,"interventionModel":91,"interventionModelDescription":88,"primaryPurpose":92,"observationalModel":88,"timePerspective":88,"maskingInfo":93},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":94,"maskingDescription":88,"whoMasked":88},"NONE","Frailty is a common age-related clinical syndrome characterized by progressive decline in physiological reserve, reduced stress tolerance, and multisystem functional impairment in older adults. It significantly increases the risk of adverse outcomes including falls, hospitalizations, functional dependence, and all-cause mortality. Chronic low-grade inflammation, immune senescence, oxidative stress, and abnormal protein modification are considered key biological mechanisms driving the onset and progression of frailty. Current mainstream interventions, such as nutritional support and physical exercise, have shown only limited efficacy in moderate to severe frailty, and targeted biological therapies for frailty remain lacking. This study aims to evaluate the efficacy and safety of plasma exchange combined with human albumin (ALB), with or without adjunctive intravenous immunoglobulin (IVIg), in the treatment of frailty, and to preliminarily explore the potential mechanisms underlying the combined therapy.\n\nThis is a prospective, randomized, exploratory clinical trial. A total of 34 participants with a FRAIL scale score of ≥ 1 will be enrolled and randomly assigned at a 1:1 ratio into two groups (17 participants in each group): the plasma exchange plus human albumin group (ALB group) and the plasma exchange plus human albumin plus intravenous immunoglobulin group (ALB + IVIg group). The study is divided into three phases: a screening phase, a treatment phase, and a follow-up phase.\n\nThe screening phase will be conducted within 7 days prior to the first treatment. Eligible subjects will sign an informed consent form and complete a comprehensive baseline assessment, including frailty status evaluation, physical function testing, routine laboratory and imaging examinations, frailty-related biomarker detection, albumin (ALB) modification profiling, and inflammatory marker testing to confirm eligibility.\n\nThe treatment phase will last for 5 months, consisting of a total of 6 treatment sessions administered monthly. Systemic assessments will be performed at each visit, including frailty status evaluation, physical function testing, routine pre-treatment examinations, frailty-related biomarker detection, ALB modification profiling, and inflammatory marker testing, to monitor treatment response and safety. Blood samples for complete blood count and coagulation function will be collected within 1 hour after the first plasma exchange session. All participants will receive plasma exchange with 5% human albumin solution as the replacement fluid, according to the study protocol. Subjects in the ALB + IVIg group will additionally receive intravenous immunoglobulin (IVIg) immediately after each plasma exchange session. Adverse events will be recorded throughout the study.\n\nFollow-up visits will be conducted at 1, 3, and 6 months after the final treatment session. All assessments and laboratory tests will be repeated to evaluate the long-term efficacy, safety, and sustained effects of the interventions.\n\nThis trial has not yet been initiated. It is expected that within-group and between-group comparisons will clarify the therapeutic effects and long-term stability of the two regimens, as well as their safety profiles. Changes in frailty-related biomarkers, inflammatory markers, and albumin modification patterns will help to illustrate the potential molecular mechanisms of plasma exchange combined with functional protein supplementation for frailty. It is hypothesized that plasma exchange combined with ALB (with or without IVIg) may exert multi-targeted intervention on frailty by eliminating aging-related toxic factors and restoring plasma and immune homeostasis. The findings of this study will provide preliminary clinical evidence and a theoretical basis for novel biological therapeutic strategies for frailty.",[97,104],{"label":98,"type":99,"description":100,"interventionNames":101},"Plasma Exchange + Human Albumin Group","EXPERIMENTAL","All subjects receive standard background therapy. Subjects receive monthly plasma exchange for 6 cycles with 5% human albumin as replacement fluid, no IVIg administration.",[102,103],"Procedure: Plasma Exchange","Biological: 5% human albumin",{"label":105,"type":99,"description":106,"interventionNames":107},"Experimental: Plasma Exchange + Human Albumin + IVIg Group","All subjects receive standard background therapy. Subjects receive monthly plasma exchange for 6 cycles with 5% human albumin replacement fluid, plus IVIg 2.5 g after each exchange session.",[102,103,108],"Biological: Intravenous immunoglobulin (IVIG)",[110,115,120],{"type":111,"name":112,"description":113,"armGroupLabels":114,"otherNames":88},"PROCEDURE","Plasma Exchange","Plasma exchange procedure, target exchange volume 50±5 mL\u002Fkg per session, flow rate 40-60 mL\u002Fmin, administered once monthly for 6 cycles.",[105,98],{"type":116,"name":117,"description":118,"armGroupLabels":119,"otherNames":88},"BIOLOGICAL","5% human albumin","Equal-volume 5% human albumin solution used as replacement fluid during plasma exchange.",[105,98],{"type":116,"name":121,"description":122,"armGroupLabels":123,"otherNames":88},"Intravenous immunoglobulin (IVIG)","IVIg administered at a fixed dose of 2.5 g per subject, infused immediately after each plasma exchange session.",[105],[125],{"name":126,"role":127,"phone":128,"phoneExt":88,"email":129},"Ying Wang","CONTACT","022-23608316","wangying@ihcams.ac.cn",[131],{"facility":5,"status":88,"city":132,"state":133,"zip":134,"country":135,"countryCode":136,"cosmosGeoPoint":137,"geoPoint":142,"contacts":143},"Tianjin","Tianjin Municipality","300041","China","CN",{"type":138,"coordinates":139},"Point",[140,141],117.17667,39.14222,{"lat":141,"lon":140},[144],{"name":88,"role":127,"phone":145,"phoneExt":88,"email":129},"02223608316",{"type":147,"investigatorFullName":88,"investigatorTitle":88,"investigatorAffiliation":88,"oldNameTitle":88,"oldOrganization":88},"SPONSOR","100657214","human-albumin-combined-with-plasma-exchange-for-frailty-intervention-100657214",false,"NCT07836127","Human Albumin Combined With Plasma Exchange for Frailty Intervention","A Prospective, Randomized Exploratory Study on the Intervention of Frailty With Human Albumin Combined With Plasma Exchange","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Clear consciousness and ability to communicate.\n3. Sufficient cognitive function and educational level to complete all study-related assessments.\n4. A score of ≥ 1 on the FRAIL scale.\n5. Voluntary written informed consent.\n\nExclusion Criteria:\n\n1. Known allergy or hypersensitivity to albumin (ALB) or intravenous immunoglobulin (IVIg).\n2. Currently receiving albumin (ALB) and\u002For intravenous immunoglobulin (IVIg) infusion for other reasons.\n3. Severe cardiac, hepatic, or renal insufficiency.\n4. Active infection or acute exacerbation of chronic infection.\n5. Current use of direct oral anticoagulants (DOACs).\n6. History of bleeding disorders or coagulation dysfunction.\n7. Concomitant malignancy or expected survival of less than 6 months.\n8. Severe visual, auditory, or motor function impairment.\n9. Refusal to sign the informed consent form.\n10. Other conditions that, in the opinion of the investigator, make the participant unsuitable for the study.","ALL","18 Years",{"count":158,"type":159},34,"ESTIMATED","INTERVENTIONAL",[162],"NA","Background Frailty is an age-related syndrome characterized by reduced physiological reserve, decreased stress tolerance and multisystem functional decline in the elderly, which markedly increases the risks of falls, hospitalization, functional impairment and all-cause mortality. Chronic low-grade inflammation, immune senescence, oxidative stress and abnormal protein modification are key mechanisms underlying the development and progression of frailty. Current mainstream interventions including nutritional support and physical exercise yield limited efficacy for moderate to severe frailty, and targeted therapies against biological aging mechanisms are still lacking.Objective To evaluate the efficacy and safety of plasma exchange combined with human albumin (ALB), with or without intravenous immunoglobulin (IVIg), in the treatment of frailty, and to preliminarily explore the potential mechanisms of the combined therapy.Methods This is a prospective, randomized, exploratory clinical trial. A total of 34 participants with a FRAIL scale score ≥ 1 will be enrolled and randomly assigned at a 1:1 ratio into two groups, with 17 cases in each group: the plasma exchange plus ALB group and the plasma exchange plus ALB plus IVIg group. The study consists of a screening phase, a 5-month treatment phase with six intervention sessions, and follow-up visits at 1, 3 and 6 months after the final treatment. Frailty status, physical function, laboratory parameters, inflammatory levels and albumin modification will be dynamically assessed throughout the trial, and adverse events will be recorded.Results The trial has not yet been initiated. It is expected that the within-group and between-group comparisons will clarify the therapeutic effects and long-term stability of the two regimens, as well as their safety profiles. Changes in biomarkers will help illustrate the potential molecular mechanisms of plasma purification combined with functional protein supplementation for frailty.Conclusion Plasma exchange combined with ALB (with or without IVIg) can exert multi-target intervention on frailty by eliminating aging-related toxic factors and restoring plasma and immune homeostasis. The findings of this study will provide preliminary clinical evidence and theoretical basis for novel biological therapeutic strategies for frailty.",[165,112],"Frailty","NOT_YET_RECRUITING","2026-09-18",{"date":169,"type":170},"2026-09-23","ACTUAL",{"date":172,"type":159},"2026-09-24",{"date":174,"type":159},"2028-11-14",{"name":5,"class":6},1]